AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.